8. AEterna Zentaris (AEZS) is a drug development company focused on oncology and endocrine therapy. The company has a product pipeline with therapeutic options at various stages of development, right from drug discovery through marketed products.
Of the 12 analysts covering the stock, 67% recommend a buy and 25% suggest a hold. The stock's average 12-month price target is $4.35, which is 105.2% higher than the current price, as per a Bloomberg consensus.
For the first quarter of 2011, the company reported revenue of $7.4 million vs. $6.4 million for the same period in 2010. Cash and cash equivalents increased to $38.3 million from $32 million in the corresponding quarter of the prior year. During the quarter, the company received a net sales royalty milestone payment of $2.5 million from Cowen Healthcare Royalty Partners.In April 2011, the company issued approximately 7.3 million common shares for aggregate gross proceeds of approximately $14.7 million. AEZS has advantages to be gained out of Perifosine -- a drug for treating multiple cancers. After the company receives license to promote the drug, as per the terms of the agreement, it would be entitled to receive $62.5 million upon achieving certain established milestone events in Japan. Besides, it is likely that AEterna Zentaris will be entitled to receive double-digit royalties on future net sales of Perifosine in the Japanese market.